105 related articles for article (PubMed ID: 27466518)
21. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
22. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
Hatam N; Ahmadloo N; Ahmad Kia Daliri A; Bastani P; Askarian M
Arch Gynecol Obstet; 2011 Jul; 284(1):215-20. PubMed ID: 20740365
[TBL] [Abstract][Full Text] [Related]
23. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous reaction associated with weekly docetaxel administration.
Chew L; Chuen VS
J Oncol Pharm Pract; 2009 Mar; 15(1):29-34. PubMed ID: 18753180
[TBL] [Abstract][Full Text] [Related]
25. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
26. Nitroxide pirolin reduces oxidative stress generated by doxorubicin and docetaxel in blood plasma of rats bearing mammary tumor.
Tabaczar S; Koceva-Chyla A; Czepas J; Pieniazek A; Piasecka-Zelga J; Gwozdzinski K
J Physiol Pharmacol; 2012 Apr; 63(2):153-63. PubMed ID: 22653902
[TBL] [Abstract][Full Text] [Related]
27. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
Lokich JJ; Moore C
Ann Intern Med; 1984 Dec; 101(6):798-9. PubMed ID: 6497196
[No Abstract] [Full Text] [Related]
29. Docetaxel in combination with fluorouracil for advanced solid tumors.
Burris HA
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):50-2. PubMed ID: 9364544
[TBL] [Abstract][Full Text] [Related]
30. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.
Miller KK; Gorcey L; McLellan BN
J Am Acad Dermatol; 2014 Oct; 71(4):787-94. PubMed ID: 24795111
[TBL] [Abstract][Full Text] [Related]
32. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
33. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
[TBL] [Abstract][Full Text] [Related]
34. Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment.
Duncker-Rohr V; Freund U; Momm F
Strahlenther Onkol; 2014 May; 190(5):491-3. PubMed ID: 24615187
[TBL] [Abstract][Full Text] [Related]
35. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Constenla M; Garcia-Arroyo R; Lorenzo I; Carrete N; Campos B; Palacios P
Gastric Cancer; 2002; 5(3):142-7. PubMed ID: 12378340
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
Kondoh C; Takahari D; Shitara K; Mizota A; Nomura M; Yokota T; Ura T; Ito S; Kawai H; Sawaki A; Muro K
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1511-5. PubMed ID: 23064062
[TBL] [Abstract][Full Text] [Related]
38. Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: an unusual cutaneous reaction to chemotherapy.
Cutler L; Wang H; Kim G; Chiu M
Int J Dermatol; 2022 Aug; 61(8):e316-e317. PubMed ID: 34351630
[No Abstract] [Full Text] [Related]
39. Incidence and implications of chemotherapy related hand-foot syndrome.
Nikolaou V; Syrigos K; Saif MW
Expert Opin Drug Saf; 2016 Dec; 15(12):1625-1633. PubMed ID: 27718746
[TBL] [Abstract][Full Text] [Related]
40. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
